-
2023-509278-41-00
5
2022-07-04
Early Stage Follicular LymphOma
-
2023-509277-22-00
4
2022-06-22
Bronchiectasis
-
2022-501180-40-00
5
2022-06-17
Ewing Sarcoma
-
2024-513446-12-00
4
2022-05-03
Living donor kidney transplantation
-
2022-501415-14-00
5
2022-03-08
moderate to severely inflamed candidiasis of the skin
-
2023-505438-85-00
5
2022-01-12
Acute myocardial infarction (AMI)
-
2024-512174-10-00
5
2021-11-11
metastatic colorectal cancer
-
2024-510578-25-00
5
2021-11-05
Histologically proven high-risk medulloblastoma, with any of the curre
-
2024-510579-40-00
9
2020-10-07
Rhabdoyosarcoma
-
2024-518077-34-00
5
2020-09-30
locally advanced rectal cancer
-
2024-514014-13-00
9
2020-09-02
female and male adult patients with acute myeloid leukemia
-
2022-501454-11-00
5
2020-02-05
standard risk ALK-positive anaplastic large cell lymphoma (ALCL)
-
2023-508926-91-00
5
2019-12-05
Stage IV childhood renal tumour with pulmonary +/- non-pulmonary
metas
-
2024-512104-19-00
6
2019-11-19
Irritable Bowel Syndrome
-
2023-508101-24-00
5
2019-08-01
Lymphoblastic lymphoma
-
2024-516110-38-00
5
2018-03-06
Hepatoblastoma and Hepatocellular Carcinoma
-
2024-512222-28-00
10
2015-06-02
Newly diagnosed with an intracranial or spinal ependymoma (all WHO gra
-
2025-520521-21-00
5
2025-09-02
Hyperlipidemia
-
2024-518457-42-00
4
2025-08-28
chronic kidney disease
-
2024-513621-23-00
5
2025-04-18
Advanced/metastatic non-small cell lung cancer (NSCLC)
-
2024-515740-23-00
5
2025-03-25
Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
-
2022-501457-37-00
5
2024-10-28
Myeloid Leukemia in Children with Down Syndrome
-
2023-503383-17-01
5
2024-10-10
Female androgenetic alopecia
-
2023-506876-28-00
5
2024-08-01
The medical condition we are investigating is type 1 AMI (STEMI and NS